Top 20 Biologics 2009 Rd Pipeline News
-
Upload
henry-zhang -
Category
Documents
-
view
71 -
download
1
Transcript of Top 20 Biologics 2009 Rd Pipeline News
1/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
TOP 20 Biologics 2009
• TOP 28 Blockbuster Biologics 2009
• TOP 14 Biologics Classes 2009
• Blockbuster Biologics 2009 by Class
• Other Antibody
• Selected Proteins
• Selected Peptides
Features:
March 10, 2010 Special Edition 1/2010
March 10, 2009
Subscribe now!
2/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
No. Previous
Year Class of Products 2009 sales
(US$ bln.) 2008 sales (US$ bln.)
Selected Branded Products
1 2 Major Cancer Antibodies 18.18 15.59 Rituxan/MabThera, Herceptin, Avastin, Erbitux, Vectibix
2 1 Anti-TNF Antibodies 18.10 16.36 Enbrel, Remicade, Humira, Cimzia
3 3 Insulin and Insulin Analogs 13.34 10.90 Humalog, Humulin, Lantus, Levemir, Novorapid, Actrapid, Novolin, Apidra
4 4 Erythropoietins 9.56 10.05 Aranesp, Procrit Eprex, Epogen, Neo-Recormon, ESPO, Dynepo, Binocrit
5 5 Interferon beta 6.06 5.35 Avonex, Rebif, Betaferon / Betaseron
6 7 Rec. Coagulation Factors 5.73 4.94 Novoseven, Kogenate, Helixate, Refacto, Advate, Recombinate, Benefix
7 6 G-CSF 5.16 5.18 Neulasta, Neupogen, Neutrogin, GRAN
8 11 Anti-Inflammatory Antibodies
3.12 2.29 Tysabri, Xolair, Orencia, Soliris, RoActemra, Arcalyst
9 9 Human Growth Hormone 2.89 2.68 Genotropin, Norditropin, Humatrope, Nutropin, Saizen, Serostim, Omnitrope
10 10 Interferon alpha 2.61 2.56 Pegasys, Peg-Intron, Intron A
11 8 Enzyme Replacement 2.42 2.80 Cerezyme, Fabrazyme, Aldurazyme, Myozyme, Replagal, Naglazyme, Elaprase
12 12 Ophthalmic Antibody
2.34 1.76 Lucentis
13 14 Follicle Stimulating Hormone
1.21 1.16 Gonal-f, Puregon/Follistim
14 13 Antiviral antibody 1.08 1.23 Synagis
Total: 91.78 82.85
Currency exchange rates as of March 10, 2010: 1 € = 1.35529 US$; 1 CHF = 0.926783 US$; 1 Yen = 0.011117 US$; 1 DKK = 0.18214 US$; 1 SEK = 0.13961 US$
3/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
TOP 20 Biologics in 2009 (by generic name)
# Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 2009 sales (vs 2008)
1 etanercept: Enbrel
TNF antagonist
Dimeric fusion protein of soluble TNF-R + Fc of Ig
Amgen & Wyeth & Takeda Pharmaceutical Co.
Antibody Rheumatoid arthritis and all other approved indications
Total: US$ 6,580 mln (6,490)
2 infliximab: Remicade
TNF alpha antagonist
Rec chimeric IgG1 mab
Centocor (J&J) & Schering-Plough & Mitsubishi Tanabe Pharma
Antibody Rheumatoid arthritis et al.
Total: US$ 5,934 mln (5,335)
3 bevacizu-mab: Avastin
VEGF Rec humanized mab
Genentech & Roche & Chugai
Antibody Metastatic colorectal cancer with 5-FU; 1st line NSCLC plus carboplatin & paclitaxel
Total: US$ 5,777 mln (4,484)
4 rituximab: Rituxan / MabThera
CD20 Rec chimeric full mab
Genentech; Biogen-IDEC, Roche
Antibody Non-Hodgkin's lymphoma (NHL) and all other approved indications
Total: US$ 5,653 mln (5,099)
5 adalimu-mab: Humira Pen
TNF alpha antagonist
Rec fully human mab
Abbott & Eisai Antibody Rheumatoid arthritis et al.
Total: US$ 5,488 mln (4,521)
6 epoetin alfa: Epogen / Procrit / Eprex / ESPO
Erythropoietin receptor (EPO-R)
Rhu protein Amgen & Ortho Biotech / Janssen-Cilag (J&J) & Kyowa Hakko Kirin Pharma
Protein Renal anemia and all other approved indications
US$ 2.569 bln + half of US$ 438.4 mln + US$ 2.245 bln Total: US$ 5,033 mln (5,123)
4/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
TOP 20 Biologics in 2009 (by generic name)
# Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 2009 sales (vs 2008)
7 trastuzu-mab: Herceptin
HER2 Rec humanized mab
Genentech; Chugai, Roche
Antibody Her2 positive metastatic breast cancer et al.
Total: US$ 4,890 mln (4,384)
8 insulin glargine: Lantus
Insulin receptor
Rhu basal insulin analog for once-daily SC injection
Sanofi-Aventis Protein Type 1 and Type 2 diabetes
Total: US$ 4,185 mln (3,130)
9 pegfilgra-stim: Neulasta
G-CSF receptor
Pegylated rec methio-nyl human G-CSF
Amgen Protein Neutropenia Total: US$ 3,355 mln (3,318)
10 darbepo-etin alfa: Aranesp / NESP
Erythropoietin receptor (EPO-R)
Engineered variant of rhu protein AutoInjector
Amgen & Kyowa Hakko Kirin Pharma
Protein Anemia US$ 2.652 bln + half of US$ 438.4 mln Total: US$ 2,871 mln (3.344)
11 ranibizu-mab: Lucentis
VEGF Rec humanized Fab for intravitreal injection
Genentech & Novartis
Antibody Wet age-related macular degeneration (AMD)
Total: US$ 2,344 mln (1,761)
12 interferon beta-1a: Avonex
Interferon beta receptor
Rhu protein for IM injection once a week
Biogen Idec Protein Relapsing forms of multiple sclerosis
Total: US$ 2,323 mln (2,203)
13 interferon beta-1a: Rebif
Interferon beta receptor
Rhu protein (prefilled syringe)
Merck Serono Protein Relapsing forms of multiple sclerosis
Total: US$ 2,087 mln (1,699)
5/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
TOP 20 Biologics in 2009 (by generic name)
# Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 2009 sales (vs 2008)
14 rhu insulin: Actrapid (EU)/ Novolin (US)
Insulin receptor
Rhu insulin (short-acting) for injection, (S. cerevisiae)
Novo Nordisk Protein Type 1 and 2 diabetes
Total: US$ 2,066 mln (2,017)
15 rec Anti-hemophilic Factor: Advate
Coagulation factor VIII replacement
Rec full length factor VIII plasma / albumin free
Baxter Healthcare
Protein Hemophilia A
US$ 2,058 mln (> 1,500) Advate and Recombinate (in process of conversion)
16 insulin lispro: Humalog Mix 50:50 premix
Insulin receptor
Soluble rhu insulin ana-log (50 %) + insuline-protamine precipitate (50 %)
Eli Lilly Protein Type 1 and 2 diabetes
Total: US$ 1,959 mln (1,734)
17 insulin aspart: NovoLog NovoRapid
Insulin receptor
Rhu insulin analog (rapid-acting)
Novo Nordisk Protein Glycemic control in children and adults with diabetes mellitus
Total: US$ 1,780 mln (1,338)
18 interferon beta-1b: Betaseron / Betaferon
Interferon beta receptor
Rhu protein Berlex & Bayer Schering Pharma
Protein All relapsing forms of multiple sclerosis
Total: US$ 1,649 mln (1,449)
19 cetuximab: Erbitux
EGF-R Rec chimeric mab
Eli Lilly (from ImClone acq.) & BMS & Merck Serono
Antibody Metastatic colo-rectal carcinoma and other labels
Total: US$ 1,629 mln (1,470)
20 peginter-feron alfa-2a: Pegasys
Interferon alpha receptor
Pegylated rhu protein
Roche Protein Chronic hepatitis C virus infection + Copegus
Total: US$ 1,538 bln (1,408)
6/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
TOP 20 Biologics in 2009 (by generic name)
# Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication 2009 sales (vs 2008)
21 epoetin beta: NeoRecor-mo / Epogin / Epoch
Erythropoietin receptor (EPO-R)
Rhu protein Roche Protein Renal anemia and all other approved indications
Total: US$ 1,450 mln (1,527) 971 + 479
22 filgrastim: Neupogen;
G-CSF receptor
Rhu protein Amgen Protein Neutropenia Total: US$ 1,341 bln (1,419)
23 eptacog alfa: NovoSeven
Induction of coagulation in the presence of alloantibodies to F. VIII
Rhu protein in BHK; now in room-temperature stable liquid formulation
Novo Nordisk Protein Prevention and treatment of hemorrhage in hemophiliacs with alloantibodies
Total: US$ 1,292 mln (1,127)
24 Rec Anti-hemophilic Factor: Kogenate FS
F. VIII substitution
Rhu protein formulated with sucrose (BHK)
Bayer Schering Pharma
Protein Hemophilia A Total: US$ 1,207 mln (1,074)
25 premix insulin aspart; NovoMix 50;
Insulin receptor
Soluble + protamine-crystallized rhu insulin analog
Novo Nordisk Protein Type 1 and 2 diabetes
Total: US$ 1,187 mln (1,032)
26 palivizu-mab: Synagis
Epitope on RS virus
Rec humanized full mab
MedImmune Antibody Propylaxis of RSV infection
Total: US$ 1,082 mln (1.230)
27 natalizu-mab: Tysabri
Alpha4/beta1/7 integrin
Rec humanized IgG4 mab
Biogen Idec & Elan
Antibody RR multiple sclerosis
Total: US$ 1,060 mln (815)
28 human insulin: Humulin 50:50
Insulin receptor
Rhu insulin (mix isophane suspension)
Eli Lilly Protein Type 1 and 2 diabetes
Total: US$ 1,022 mln (1,063)
7/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 1: Cancer Antibodies
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
1891
Avastin; bevacizumab
Vascular endothelial growth factor (VEGF)
Rec humanized mab
Roche Antibody 1st and 2nd line metastatic colorectal cancer with 5-FU-based chemotherapy
Mar-ket
Roche PR Feb 3, 2010 - 2009 worldwide sales of Avastin were CHF 6,222 mln (+ 21 % in local currency vs 2008) corresponding to US$ 5,777 mln
1825
Rituxan / MabThera; rituximab;
CD20 Rec chimeric full mab
Roche (Genentech) & Biogen-IDEC
Antibody Non-Hodgkin's B-Cell Lymphoma
Mar-ket
Roche PR Feb 3, 2010 - 2009 sales of CHF 6,087 mln (+ 6 % in local currencies vs 2008) corresponding to US$ 5,653 mln
1869
Herceptin; trastuzumab
HER2 Rec humanized mab
Roche (Genentech & Chugai)
Antibody Her2 positive metastatic breast cancer and all other approved indications
Mar-ket
Roche PR Feb 3, 2010 - 2009 sales of CHF 5,266 mln (+ 8 % in local currencies vs 2008) corresponding to US$ 4,890 mln
1847
Erbitux; cetuximab; IMC-C225; EMD-271786
EGF-R Rec chimeric mab
Eli Lilly (from ImClone acquisition) & Bristol-Myers Squibb (BMS) & Merck Serono
Antibody Irinotecan refractory metastatic colorectal carcinoma and all other approved indications
Mar-ket
BMS PR Jan 28, 2010 - North American sales by BMS in 2009 were US$ 683 mln (- 9 % vs 2008); 2009 sales in Merck Serono territories were € 697 mln (+ 23 % vs 2008) corresponding to US$ 946.4 mln. Total sales of US$ 1,629 mln
1790
Vectibix; panitumu-mab
EGF-R Rec fully human IgG2 full mab
Takeda Pharmaceutical Co. & Amgen
Antibody 3rd line metastatic colorectal cancer et al
Mar-ket
Amgen PR Jan 25, 2010 - 2009 sales of US$ 233 mln (+ 52 % vs 2008)
Total = US$ 18.182 bln
8/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 2: TNF Antagonist Biologics
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
6605
Enbrel; etanercept
TNF antagonist
Dimeric fusion protein of soluble TNF-R + CH2 and CH3 domains of Fc of Ig
Amgen & Pfizer (acquired Wyeth) & Takeda Pharmaceutical Co.
Antibody Moderate to severe rheumatoid arthritis
Mar-ket
Amgen PR Jan 25, 2010 - Amgen in US and Canada: US$ 3,493 mln (- 3 % vs 2008); Wyeth: 6-mth revenues outside US and Canado of US$ 1,363 mln extrapolated to 12-mths sales of US$ 2,726 source Takeda: 9-mths (Apr-Dec) 2009 sales of Yen 24.5 bln (+ 20.5 %), extrapolated to 1-yr: Yen 32.6 bln source corresponding to US$ 361.4 mln. Total sales of US$ 6,580 mln
6587
Remicade; infliximab
TNF alpha antagonist
Rec chimeric IgG1 mab
Centocor (J&J) & Merck & Co. (acquired Schering-Plough) & Mitsubishi Tanabe Pharma
Antibody Moderately to severely active rheumatoid arthritis
Mar-ket
Merck & Co 2009 Product Sales Feb 16, 2010 – Merck: US$ 2,327 mln (+ 9.9 %); J&J: US$ 3,088 mln (+ 9.9 % vs 2008) and exports to partners of US$ 987 mln source MTP’s forecast of fiscal year 2009 sales are Yen 46.8 bln source corresponding to US$ 519 mln. Total sales of US$ 5,934 mln
6571
Humira Pen; adalimumab;
TNF alpha antagonist
Rec fully human mab
Abbott & Eisai Antibody Moderate to severe rheumatoid arthritis
Mar-ket
Abbott PR JAn 27, 2010 - 2009 sales of US$ 5,488 mln (+ 21.4 % vs 2008); Eisai reports YOY sales of Yen 4.8 bln (+ 311 %) source corresponding to US$ 53.2 mln
650 CIMZIA; certolizumab pegol; CDP-870
TNF-alpha (soluble and membrane bound)
PEGylated rec human-ized Fab' fragment
UCB Pharma (ex Celltech)
Antibody Moderate to severe Crohn's disease and RA
Mar-ket
UCB PR Mar 2, 2010 - 2009 sales were € 70 mln (+ 600 % vs 2008) corresponding to US$ 95.1 mln
Total: US$ 18.097 bln
9/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 3: Insulin - I
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
1379
Lantus; insulin glargine
Insulin receptor
Rhu basal insulin analog for once-daily SC injection
Sanofi-Aventis Protein Type 1 and Type 2 diabetes
Mar-ket
Sanofi-Aventis PR Feb 10, 2010 - 2009 sales of € 3,080 mln (+ 22.5 % vs 2008) corresponding to US$ 4,185 mln
1380
Actrapid (EU)/ Novolin (US); rhu insulin
Insulin receptor
Rhu insulin (short-acting) for injection, produced in S.cerevisiae
Novo Nordisk Protein Type 1 and 2 diabetes
Mar-ket
Novo Nordisk PR Feb 2, 2010 - 2009 sales of human insulin product group was DKK 11,315 (- 5 % in local currencies vs 2008) corresponding to US$ 2,066 mln
1324
Humalog Mix 50:50; premix insulin lispro
Insulin receptor
Mixture of soluble rhu insulin analog (50 %) with insuline-protamine precipitate (50 %)
Eli Lilly Protein Type 1 and 2 diabetes
Mar-ket
Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 1,959 mln (+ 13 % vs 2008)
1223
NovoLog (US) / NovoRapid (EU); insulin aspart
Insulin receptor
Rhu insulin analog (rapid-acting) for injection, produced in S.cerevisiae
Novo Nordisk Protein Glycemic control in children and adults with diabetes mellitus
Mar-ket
Novo Nordisk PR Feb 2, 2010 - 2009 sales of DKK 9.749 mln (+ 22 % in local currencies vs 2008) corresponding to US$ 1,780 mln
10/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 3: Insulin - II
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
6984
NovoMix 50; premix insulin aspart
Insulin receptor
Soluble (50 %) and protamine-crystallized (50 %) rhu insulin analog aspart
Novo Nordisk Protein Type 1 and 2 diabetes
Mar-ket
Novo Nordisk PR Feb 2, 2010 - 2009 sales of product group was DKK 6,499 (+ 15 % in local currencies vs 2008) corresponding to US$ 1,187 mln
8893
Humulin 50:50; premix human insulin
Insulin receptor
Rhu insulin produced in E.coli, mix of 50 % soluble human insulin and 50 % insulin isophane suspension
Eli Lilly Protein Type 1 and 2 diabetes
Mar-ket
Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 1,022 mln (- 4 % vs 2008)
1238
Levemir; insulin detemir
Insulin receptor
Rec human basal insulin analogue for once-daily injection
Novo Nordisk Protein Children and adults with insulin-dependent diabetes
Mar-ket
Novo Nordisk PR Feb 2, 2010 - 2009 sales of DKK 5,223 (+ 35 % in local currencies vs 2008) corresponding to US$ 954 mln
6982
Apidra; insulin glulisine
Insulin receptor
Mealtime short acting rhu insulin analog
Sanofi-Aventis Protein Type 1 and 2 diabetes mellitus
Mar-ket
Sanofi-Aventis PR Feb 10, 2010 - 2009 sales of € 137 mln (+ 38.8 % vs 2008) corresponding to US$ 185.9 mln
Total = US$ 13.339 bln
11/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 4: Erythropoiesis Stimulating Agents (ESA) - I
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
52 Aranesp; darbepoetin alfa
Erythropoietin receptor (EPO-R)
Engineered variant of rec hu hormone + AutoInjector
Amgen Protein Chronic kidney disease (once monthly) and all other approved indications
Mar-ket
Amgen PR Jan 25, 2010 - 2009 sales of US$ 2,652 mln (- 15 % vs 2008)
165 NESP; darbepoetin; KRN-321
Erythropoietin receptor (EPO-R)
Glycoengineered rhu protein
Kyowa Hakko Kirin Pharma (from Amgen)
Protein Renal anemia Mar-ket
Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of NESP and ESPO in 2009 were Yen 39.6 bln (+ 15 % vs 2008) = US$ 438.4 mln
161 Epogen; epoetin alfa
Erythropoietin receptor (EPO-R)
Rhu erythropoietin alfa
Amgen Protein Renal anemia and all other approved indications
Mar-ket
Amgen PR Jan 25, 2010 - 2009 sales of US$ 2,569 mln (+ 5 % vs 2008)
162 ESPO; epoetin alfa
Erythropoietin receptor (EPO-R)
Rhu protein Kyowa Hakko Kirin Pharma (from Amgen)
Protein Renal anemia Mar-ket
Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of NESP and ESPO in 2009 were Yen 39.6 bln
1899
Procrit / Eprex / Erypo; epoetin alfa
Erythropoietin receptor (EPO-R)
Rec human glycoprotein
Ortho Biotech / Janssen-Cilag (J&J) (from Amgen)
Protein Chemotherapy induced anemia and all other approved indications
Mar-ket
J&J 2009 Product Sales Jan 26, 2010 - 2009 sales were US$ 2,245 mln (- 8.7 %)
163 Neo-Recormon; epoetin beta
Erythropoietin receptor (EPO-R)
Rhu protein Roche Protein Renal anemia and all other approved indications
Mar-ket
Roche PR Feb 3, 2010 - 2009 international sales of NeoRecormon except US and Japan were CHF 1045 mln corresponding to US$ 971 mln: combined sales of Epogin and NeoRecormon were CHF 1560 mln (- 11 % vs 2008)
12/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 4: Erythropoiesis Stimulating Agents - II
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
164 Epogin; Epoch; epoetin beta
Erythropoietin receptor (EPO-R)
Rhu erythropoietin beta
Roche (Chugai)
Protein Renal anemia. Chemotherapy induced anemia
Mar-ket
Roche PR Feb 3, 2010 - 2009 sales in Japan of Epogin were CHF 515 mln (-1% vs 2008) corresponding to US$ 479 mln
207 Mircera; Methoxy polyethylene glycol-epoetin beta; CERA
Erythropoietin receptor (EPO-R)
Continuous erythro-poiesis receptor activator (pegylated)
Roche Protein Renal anemia due chronic kidney disease +/- dialysis
Mar-ket
Roche PR Feb 3, 2010 - Worldwide sales in 80 countries in 2009 was CHF 179 mln (+ 252 % vs 2008) corresponding to US$ 166 mln
173 Binocrit / Epoetin alfa Hexal / Abseamed; epoetin alfa
Erythropoietin receptor (EPO-R)
Rhu erythro-poietin
Sandoz (Novartis) & Medice
Protein Renal anemia Mar-ket
Novartis Results Presentation Jan 26, 2010 - 2009 sales of approx. US$ 50 mln (+ approx. 60 % vs 2008)
166 Dynepo; epoetin delta
Erythropoietin receptor (EPO-R)
Rhu protein from gene activation technology (human cell line)
Shire Protein Renal anemia. Renal anemia with two new dosing regimens
Mar-ket
Shire PR Feb 19, 2009 - Shire ceased commercialization of Dynepo at the end of 2008
Total: US$ 9.562 bln
13/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 5: Interferon beta
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
1556
Avonex; interferon beta-1a
Interferon beta receptor
Rhu protein for IM injection once a week
Biogen Idec Protein Relapsing forms of multiple sclerosis
Mar-ket
Biogen Idec PR Feb 9, 2010 - 2009 sales of US$ 2,323 mln (+ 5 % vs 2008)
1534
Rebif; interferon beta-1a
Interferon beta receptor
Rhu protein (prefilled syringe)
Merck Serono Protein Relapsing forms of multiple sclerosis
Mar-ket
Merck KGaA PR FEb 23, 2010 - 2009 sales of € 1,537 mln (+ 15 % vs 2008) corresponding to US$ 2,087 mln
1501
Betaseron / Betaferon; interferon beta-1b
Interferon beta receptor
Rhu protein Berlex & Bayer Schering Pharma
Protein All relapsing forms of multiple sclerosis
Mar-ket
Bayer Briefing Feb 26, 2010 - 2009 sales of € 1,214 mln (+ 5.7 % in local currencies vs 2008) corresponding to US$ 1,649 mln
Total: US$ 6.059 bln
14/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 6: Coagulation Factors
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
106 Advate; octocog alfa; antihemo-philic factor plasma/ albumin-free
Coagulation factor VIII replacement
Rec full length coagulation factor VIII plasma/ albumin free
Baxter Healthcare
Protein Hemophilia A
Mar-ket
Baxter 2009 Product Line Sales Jan 28, 2010 - Combined sales of Advate and Recombinate in 2009 were US$ 2,058 mln (+ 5 % vs 2008) continued customer adoption of Advate over Recombinate
117 NovoSeven; eptacog alfa; rFVII
Substitution of coagulation F. VIIa
Rhu activated factor VII in BHK
Novo Nordisk (from Zymogenetics)
Protein Hemorrhage in hemophiliacs with alloantibodies
Mar-ket
Novo Nordisk PR Feb 2, 2010 - 2009 sales of DKK 7,072 mln (+ 10% in local currencies vs 2008) corresponding to US$ 1,292 mln
119 Kogenate FS (BAY 14-2222) + BIO-SET
F. VIII substitution
Rhu protein formulated with sucrose (BHK)
Bayer Schering Pharma
Protein Hemophilia A Mar-ket
Bayer Briefing Feb 26, 2010 - 2009 sales: € 888 mln (+ 3.2 % in local currencies vs 2008) = US$ 1,207 mln (incl. transfer sales to CSL)
150 BeneFix; nonacog alfa
F. IX substitution
Rec hu protein
Pfizer (acquired Wyeth) & Biovitrum
Protein Hemophilia B Mar-ket
Pfizer 2009 Financial Report - Sales in last 2.5 mths of US$ 98 mln, extrapolated to 12-mths sales of approx. US$ 479 mln
10106
Helixate FS / Helixate NexGen
F. VIII substitution
Rhu protein formulated with sucrose
CSL Behring (manufactured by Bayer Schering Pharma)
Protein Hemophilia A Mar-ket
CSL Presentation Feb 12, 2010 - Sales in H1 (Jul-Dec) of FY 2009/20 were US$ 247 mln and in H1 of 2009 were US$ 220 mln source calendar year 2009: US$ 467 mln
114 Xyntha (USA); moroctocog alfa (AF-CC)
Substitution of coagulation factor VIII
Albumin free (AF) rhu B-domain deleted factor VIII
Pfizer (acquired Wyeth) & Biovitrum
Protein Hemophilia A Mar-ket
Pfizer 2009 Financial Report - Combined product sales of Xyntha/ Refacto in last 2.5 mths after acquisition of Wyeth by Pfizer was US$ 47 mln extrapolated to 12-mths sales: approx US$ 225 mln
Total = US$ 5.728 bln
15/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 7: Granulocyte Colony Stimulating Factor (G—CSF)
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
1874
Neulasta; pegfilgrastim
G-CSF receptor
Pegylated rec methionyl human G-CSF
Amgen Protein Myelosuppressive chemotherapy with at least 17 % risk of febrile neutropenia
Mar-ket
Amgen PR Jan 25, 2010 - 2009 sales of US$ 3,355 mln (+ 1 % vs 2008)
1943
Neupogen; filgrastim
G-CSF receptor
Rhu protein Amgen Protein Neutropenia Mar-ket
Amgen PR Jan 25, 2010 - 2009 sales were US$ 1,288 mln (- 4 % vs 2008)
9986
Neu-up; nartograstim
G-CSF receptor
Rhu protein Kyowa Hakko Kirin Pharma
Protein Neutropenia Mar-ket
Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of Neu-up and Gran in 2009 were Yen 13.8 bln (- 3 % vs 2008) corresponding to US$ 153 mln
9983
Gran; filgrastim
G-CSF receptor
Rhu protein Kyowa Hakko Kirin Pharma (from Amgen)
Protein Neutropenia Mar-ket
Kyowa Hakko Kirin 2009 Results Presentation Jan 29, 2010 - Combined sales of Neu-up and Gran in 2009 were Yen 13.8 bln (- 3 % vs 2008)
2345
Neutrogin; lenograstim
G-CSF receptor
Rhu protein Chugai & Roche
Protein Chemotherapy-induced neutropenia
Mar-ket
Roche Results Presentation Feb 3, 2010 - 2009 sales by Chugai in Japan were CHF 385 mln (- 14 % vs 2008) = US$ 358 mln
9378
Zarzio; filgrastim
G-CSF receptor
Generic equivalent of Neupogen from Amgen
Sandoz (Novartis)
Protein Neutropenia
Mar-ket
Novartis Results Presentation Jan 26, 2010 - 2009 sales of approx. US$ 8 mln (launched during 2009 in Germany, France, Spain, Poland and Austria)
Total = US$ 5.162 bln
16/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 8: Anti-Inflammatory Antibodies
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
1476
Tysabri; Antegren; natalizumab; AN100226
Alpha4/beta1/7 integrin
Rec humanized IgG4 mab
Biogen Idec & Elan
Antibody RR multiple sclerosis
Mar-ket
Biogen Idec PR Feb 9, 2010 - 2009 global in-market sales of US$ 1,060 mln (+ 30 % vs 2008) of which 509 mln were generated in the US and 551 mln outside the US
90 Xolair; omalizumab;
IgE Rec humanized mab
Roche (Genentech) & Novartis
Antibody Severe allergic asthma in adults and adolescents (age 12 or above)
Mar-ket
Roche Results Presentation Feb 3, 2010 - US sales by Roche: CHF 620 mln (+ 10 % vs 2008) = US$ 576 mln; Novartis sales: US$ 338 mln (+ 65 % in local currencies) source Total sales of US$ 914 mln
6537
Orencia; abatacept; CTLA4-Ig
B7-1 (CD80) and B7-2 (CD86)
Rec fusion protein of CTLA4+ Fc of IgG1 (hinge, CH2 + CH3)
Bristol-Myers Squibb
Antibody Adult rheumatoid arthritis and juvenile idiopathic arthritis
Mar-ket
BMS PR Jan 28, 2010 - 2009 sales of US$ 602 mln (+ 37 % vs 2008)
37 Soliris; eculizumab; H5G1.1
Complement C5 antagonist
Rec human-ized (hybrid IgG2/4) full mab
Alexion Phar-maceuticals
Antibody Paroxysmal nocturnal hemoglobinuria (PNH)
Mar-ket
Alexion Pharmaceuticals PR Feb 11, 2010 - 2009 sales of US$ 386.8 mln (+ 46 % vs 2008)
6545
RoActemra (EU); Actemra; tocilizumab
Interleukin-6 receptor (IL-6R) antagonist
Rec humanized mab
Roche (Chugai)
Antibody Moderate to severe rheuma-toid arthritis (RA)
Mar-ket
Roche PR Feb 3, 2010 - Available in 25 countries, 2009 sales were CHF 146 mln (+ 289 % vs 2008) corresponding to US$ 135.5 mln
6546
ARCALYST; rilonacept; Il-1 trap
Interleukin-1 (IL-1) antagonist
Trap (2 IL receptor do-mains + CH2 +CH3 of Fc)
Regeneron Pharma-ceuticals
Antibody Cryopyrin-asso-ciated periodic syndromes (CAPS)
Mar-ket
Regeneron Pharmaceuticals PR Feb 18, 2010 - 2009 net product sales of US$ 18.4 mln (+ 192 % vs 2008)
Total: US$ 3.117 bln
17/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 9 Human Growth Hormone (hGH)
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
1289
Genotropin; somatropin
hGH) receptor
Rhu protein with SC inj. devices
Pfizer Protein Growth hormone deficiency
Mar-ket
Pfizer 2009 Financial Report - 2009 sales of US$ 887 mln (- 0.6 % vs 2008)
1291
Norditropin; somatropin
hGH receptor Rhu protein Novo Nordisk Protein Growth hormone deficiency
Mar-ket
Novo Nordisk PR Feb 2, 2010 - DKK 4,401 mln (+ 10 % in local currencies) = US$ 804 mln
1290
Humatrope; somatropin
hGH receptor Rhu protein for SC injection
Eli Lilly Protein Growth hormone deficiency
Mar-ket
Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 448.8 mln (- 4.1 % vs 2008)
1288
Nutropin; Nutropin AQ; somatropin
hGH receptor Rhu protein Genentech (Roche)
Protein Growth hormone deficiency
Mar-ket
Roche Results Presentation Feb 3, 2010 - 2009 sales in Roche territories were CHF 400 mln (+ 3 % in local currencies vs 2008) corresponding to US$ 371.8 mln
1292
Saizen; somatropin
hGH receptor Rhu protein Merck Serono Protein Growth hormone deficiency
Mar-ket
Merck KGaA PR Feb 23, 2010 - 2009 sales of € 191 mln (+ 11 % vs 2008) corresponding to US$ 259.6 mln
1239
Omnitrope; somatropin
Human growth hormone (hGH) receptor
Rhu protein (Generic equivalent of Genotropin from Pfizer
Sandoz (Novartis)
Protein Growth hormone deficiency
Mar-ket
Novartis Results Presentation Jan 26, 2010 - 2009 sales of approx. US$ 60 mln (+ approx. 55 % vs 2008)
8750
Nutropin AQ; somatropin
hGH receptor Rhu protein Ipsen (from Genentech)
Protein Growth hormone defiency
Mar-ket
Ipsen PR Feb 1, 2010 - 2009 sales of € 40.4 mln (+ 26.5 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 54.8 mln
Total: US$ 2.886 bln
18/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 10: Interferon alpha
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
861 Pegasys; peg-interferon alfa-2a
Interferon alpha receptor
Pegylated rhu protein
Roche Protein Chronic hepatitis C virus infection + Copegus
Mar-ket
Roche PR Feb 3, 2010 - 2009 sales of CHF 1,655 mln (+ 5 % in local currencies vs 2008) corresponding to US$ 1,538 mln
794 PegIntron; pegylated interferon alfa-2b
Interferon alpha receptor
Pegylated (12 kDa) rec human protein
Merck & Co. (acquired Schering-Plough)
Protein Hepatitis C virus infection plus/minus ribavirin; retreatment after previous IFN treatment failure
Mar-ket
Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 844 mln (- 7.7 % vs 2008)
920 Intron A; interferon alpha-2b
Interferon alpha receptor
Rhu protein Merck & Co. (acquired Schering-Plough)
Protein HCV infection Mar-ket
Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 231 mln (-1 1.3 % vs 2008)
Total: US$ 2.613 bln
19/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 11: Enzyme Replacement Therapies
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
7822
Cerezyme; imiglucerase
Beta-gluco-cerebrosidase enzyme replacement
Rhu protein Genzyme Protein Type 1 Gaucher disease
Mar-ket
Genzyme PR Jan 12, 2010 - 2009 sales were US$ 793 mln (- 34 % vs previous year) - due to manufacturing problems
1176
Fabrazyme; agalsidase beta
Alpha-galactosidase A enzyme replacement
Rhu protein Genzyme Protein Fabry disease Mar-ket
Genzyme PR Jan 12, 2010 - 2009 sales were US$ 431 mln (- 13 % vs previous year) - due to manufacturing problems
1157
Elaprase; idursulfase; iduronate-2-sulfatase
Iduronate-2-sulfatase enzyme replacement
Rhu protein Shire & Genzyme
Protein Hunter syndrome (MPS-II)
Mar-ket
Shire PR Feb 19, 2010 - 2009 sales of US$ 353 mln (+ 20 % on a constant exchange rate basis vs 2008)
1192
Lumizyme; Myozyme; alglucosidase alpha
Alglucosidase alpha replacement
Rec hu enzyme
Genzyme Corp
Protein Pompe disease Mar-ket
Genzyme PR Jan 12, 2010 - 2009 sales of US$ 324 mln (+ 9 % vs previous year)
1381
Replagal; GA-agalsida-se alfa
Alpha-galactosidase ERT
Rhu protein Shire & Dainippon Sumitomo
Protein Fabry disease Mar-ket
Shire PR Feb 19, 2010 - US$ 194 mln (+ 16 % on a constant exchange rate basis vs 2008)
1161
Naglazyme; galsulfase; rhASB
Arylsulfatase B enzyme replacement
Rhu protein Biomarin Pharmaceutical & AnGes MG
Protein Mucopolysaccharidosis VI (MPS VI)
Mar-ket
BioMarin Pharmaceuticals PR Feb 24, 2010 - 2009 sales were US$ 168.7 mln (+ 27.1 % vs 2008)
1159
Aldurazyme; laronidase
Alpha-L-iduronidase enzyme replacement
Rhu protein Biomarin Phar-maceuticals & Genzyme
Protein Mucopolysaccharidosis I (MPS I)
Mar-ket
BioMarin Pharmaceuticals PR Feb 24, 2010 - 2009 sales reported by Genzyme were US$ 155.1 mln (+ 2.5 % vs 2008)
1385
VPRIV; velaglucer-ase alfa
Human gluco-cerebrosidase ERT
Rhu protein, gene-activated
Shire Protein Type 1 Gaucher's disease
Mar-ket
Shire Presentation Feb 19, 2010 - 2009 sales of US$ 3 mln; launches in EU and US start in 2010
Total: US$ 2.422 bln
20/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 12: Ophthalmic Antibody
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
6306
Lucentis; ranibizumab; RG3645; RG-3645
Vascular endothelial growth factor (VEGF)
Rec humanized Fab for intravitreal injection
Roche (Genentech) & Novartis
Antibody Wet age-related macular degeneration (AMD)
Mar-ket
Roche PR Feb 3, 2010 - US sales by Roche (Genentech) in 2009 were CHF 1,198 mln (+ 24 % vs 2008) corresponding to US$ 1,112 mln; 2009 sales by Novartis in more than 80 countries were US$ 1,232 mln (+ 47 % in local currencies vs 2008) source Total sales of US$ 2,344 mln
Group 13: Follicle Stimulating Hormone (FSH)
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
1319
Puregon / Follistim; follitropin beta
Follicle Stimulating Hormone (FSH) receptor
Rhu glycoprotein produced in CHO cells, available in vials and cartridges
Merck & Co. (acquired Schering-Plough) (ex Organon))
Protein Development of multiple follices in ovulatory women and in anovulatory infertile women
Mar-ket
Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 546 mln (- 5.4 % vs 2008)
1260
Gonal-f; rec follitropin alpha; GONALEF; FSH
Follicle Stimulating Hormone (FSH)
Rec human protein
Merck Serono Protein Induction of ovulation and pregnancy in functionally infertile pts
Mar-ket
Merck KGaA PR Feb 23, 2010 - 2009 sales of € 486 mln (+ 5.8 % vs 2008) corresponding to US$ 660.4 mln
Total: US$ 1.206 bln
21/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group 14: Antiviral Antibody
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
734 Synagis; palivizumab; MEDI-493;
Epitope on RS virus
Rec humanized full mab
AstraZeneca (MedImmune)
Antibody Propylaxis of RSV infection
Mar-ket
AstraZeneca PR Jan 28, 2010 - 2009 sales of US$ 1,082 mln (- 12 %)
Group: Other Antibodies
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
217 ReoPro; abciximab
Glycoprotein IIb/IIIa antagonist
Fab fragment of chimeric mab 7E3
Eli Lilly & Centocor (J&J)
Antibody Adjunct to PCI (percutaneous coronary interventions)
Mar-ket
Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 231.5 mln (- 9.7 %)
22/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group: Selected Proteins - I
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
440 Pulmozyme; dornase alfa
DNA Rhu enzyme delivered with nebulizer
Roche (Genentech)
Protein Cystic fibrosis Mar-ket
Roche Results Presentation Feb 3, 2010 - 2008 sales by Roche were CHF 501 mln (+ 5 % in local currencies vs 2008) corresponding to US$ 466 mln
10016
InductOs; rhBMP-2/ACS; dibotermin alfa applied to Absorbable Collagen Sponge
Bone regeneration
Rhu bone morphogenic protein on collagen matrix
Pfizer (acquired Wyeth) & Astellas Pharma
Medical device & biomaterial
Acute tibia fractures; lower back spine fusion surgery (plus cage)
Mar-ket
Medtronic PR Feb 23, 2010 - Medtronic sales of Biologics from Jan to Dec 2009 were US$ 866 mln of which Wyeth usually received 50 % = US$ 433 mln (+ 11 % vs 2008)
151 TNKase; Metalyse; tenecteplaseTNK-t-PA
Plasminogen activator
Rec engineered t-PA (3 aa substituted)
Roche (Genentech) & Boehringer Ingelheim
Protein Acute myocardial infarction
Mar-ket
Roche Results Presentation Feb 3, 2010 - 2009 sales Activase and TNKase in Roche territories were CHF 455 mln (+ 34 % in local currencies vs 2008) corresponding to US$ 423 mln; BI results not yet published
10063
Thyrogen; TSH alfa for injection
Thyroid hormone receptor stimulator
Rec human thyrotropin (TSH) for injection
Genzyme Protein Adjunctive treatment in thyroidectomy for well-differentiated thyroid cancer
Mar-ket
Genzyme PR Feb 17, 2010 - 2009 sales of US$ 170.6 mln (+ 15 % vs 2008)
64 Xigris; drotrecogin-alpha; rhu activated protein C
F. Va + F. VIIIa; PAI-1; TNF; thrombin
Rec hu protein
Eli Lilly & Teijin
Protein Severe sepsis Mar-ket
Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 127.3 mln (- 20.8 %)
23/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group: Selected Proteins - II
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
6686
Kineret; anakinra;
Interleukin-1 receptor (IL-1R) antagonist
Rhu protein (non-glycosylated, N-terminal methionin)
Biovitrum (from Amgen)
Protein Rheumatoid arthritis
Mar-ket
Biovitrum 2009 Results Presentation Feb 18, 2010 - 2009 global sales of SEK 440.7 mln corresponding to US$ 61.6 mln
1149
Increlex; mecasermin; rhIGF-1
Insulin-like growth factor-1 ( IGF-1) receptor agonist
Rhu growth factor
Ipsen (acquired Tercica)
Protein Severe forms of primary IGF deficiency (IGFD) in children
Mar-ket
Ipsen PR Feb 1, 2010 - 2009 sales of € 21 mln (+ 286 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 28.5 mln
1785
Kepivance; palifermin; rhu KGF-1; FGF-7
Keratinocyte growth factor receptor
Rec human KGF
Biovitrum (from Amgen)
Protein Severe oral mucositis in pts with hematologic cancers undergoing bone marrow transplantation
Mar-ket
Biovitrum 2009 Results Presentation Feb 18, 2010 - 2009 global sales were SEK 109.9 mln corresponding to US$ 15.4 mln
24/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group: Selected Peptides - I
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
10105
Copaxone; glatiramer acetate
MHC class II modulator
4-aa poly-peptide at 20 mg daily SC dose
Teva Phar-maceutical Industries & Sanofi-Aventis
Peptide Relapsing-remitting multiple sclerosis
Mar-ket
Teva PR Feb 16, 2010 - 2009 global in-market sales of US$ 2,826 mln (+ 25 % vs 2008)
10107
Botox; onabotuli-numtoxinA
Neuromus-cular transmission (SNAP-25 cleavage)
Neurotoxin from Clostridium botulinum type A
Allergan Phar-maceuticals & GlaxoSmith-Kline Japan & China)
Peptide Medical and esthetic indications
Mar-ket
Allergan SEC 10-K Feb 26, 2010 - 2009 Allergan sales of US$ 1,309.6 mln (vs 1,310.9 mln in 2008); 52 % for medical and 48 % for cosmetic indications
10021
Sandostatin LAR; octreotide/IM injection
Somatostatin receptor
Somatostatin analogue, once-monthly
Novartis Peptide Acromegaly; gastro-entero-pancreatic neuroendocrine (GEP NE) tumors
Mar-ket
Novartis PR Jan 26, 2010 - 2009 sales of US$ 1,155 mln (+ 7 % in local currencies vs 2008)
2403
Velcade; bortezomib; PS-341
Proteasome inhibitor
Modified dipeptidyl boronic acid
Takeda Pharmaceutical Co. (ex Millennium) & Johnson & Johnson (J&J)
Peptide Multiple myeloma and all other approved indications
Mar-ket
J&J 2009 Product Sales Jan 26, 2010 - 2009 sales ex US reported by J&J were US$ 933 mln (+ 18.6 % vs 2008)
1169
Forteo; teriparatide; rec hu PTH(1-34);
PTH receptor Rec variant of human parathyroid hormone
Eli Lilly Peptide Osteoporose in postmenopausal women and all other approved indications
Mar-ket
Lilly 2009 Product Sales Jan 28, 2010 - 2009 sales of US$ 816.7 mln (+ 4.9 % vs 2008)
2392
Lupron / Leuplin; leuprorelin
LH-RH agonist
Nonapeptide Takeda Pharmaceutical & Abbott
Peptide Prostate cancer Mar-ket
Abbott PR JAn 27, 2010 - Abbott reported 2009 sales in its territories of US$ 800 mln (+ 22.8 % vs 2008); Takeda territories not yet reported
25/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
Group: Selected Peptides - II
ID No.
Product Name
Target / Mechanism of Action
Class of Compound
Company Product Category
Indication R&D Stage
Message
7948
Byetta; exenatide; LY2148568
GLP-1 receptor agonist
SC 39-aa synthetic peptide bid
Amylin Phar-maceuticals & Eli Lilly
Peptide Type 2 diabetes monotherapy et al
Mar-ket
Lilly PR Jan 28, 2010 - 2009 worldwide sales of US$ 796.5 mln (+ 6 % vs 2008)
10060
Decapeptyl SR; triptorelin acetate
LHRH agonist/ GnRH analog
Synthetic decapeptide with slow release formulation
Ipsen Peptide Locally advanced prostate cancer; endometriosis; uterine fibroids prior to surgery
Mar-ket
Ipsen PR Feb 1, 2010 - 2009 sales of € 250.5 mln (+ 1.4 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 340 mln
231 Integrilin; eptifibatide
GP IIb/IIIa Cyclic heptapeptide
Merck & Co. (acquired S-P) & Takeda (ex Millennium)
Peptide Acute coronary syndrome
Mar-ket
Merck & Co 2009 Product Sales Feb 16, 2010 - 2009 sales of US$ 295 mln (- 6 % vs 2008)
1564
Dysport (EU); Reloxin (US); abobotuli-numtoxinA
Neuromus-cular transmission (SNAP-25 cleavage)
Peptide for injection
Ipsen Peptide Cervical dystony
Mar-ket
Ipsen PR Feb 1, 2010 - 2009 sales of € 163.8 mln (+ 18 % on constant currency exchange rate basis vs 2008) = US$ 222.4 mln; Ipsen's sales figure includes supply to Medicis and Galderma
1172
Somatuline Autogel / Depot; lanreotide acetate
Somatostatin analog
Peptide in ready-to-use prefilled syringe
Ipsen Peptide Acromegaly Mar-ket
Ipsen PR Feb 1, 2010 - 2009 sales of € 140 mln (+ 18.2 % on a constant currency exchange rate basis vs 2008) corresponding to US$ 190.2 mln
874 Fuzeon needle free device; enfuvirtide
HIV entry inhibitor (fusion of HIV with CD4)
Linear 36-aa peptide + needle-free device
Trimeris & Roche
Peptide HIV Mar-ket
Trimeris PR Feb 02, 2010 - 2009 sales as repoted by Roche were US$ 112.2 mln (- 33 % vs 2008)
1205
Symlin; pramlintide
Amylin receptor
Synthetic amylin analog
Amylin Phar-maceuticals
Peptide Type 1 and 2 diabetes
Mar-ket
Amylin Pharmaceuticals PR Jan 27, 2010 - 2009 sales of US$ 86.4 mln (vs 86.8 mln in 2008)
26/26 La Merie S.L. | Email [email protected] | Internet www.lamerie.com
TOP 20 Biologics 2009 March 10, 2010 | Special Edition 1
• To keep up-to-date.
Examine the who, what, when, where of biotechnology R&D.
• To benchmark your company against the competition
Keep en eye on your competitors’ projects and developments, in which stage they are, their achievements, handicaps, etc…and find out where you are standing in the market.
• To save time in your research
Get the crucial information, in a one-shot tabular screen grouped in Therapeutic Areas or Product Categories, and deepen easily in those articles in which you are interested with just one-click.
• To identify new business enterprises
Recognize new business opportunities: joint ventures, licensing partners, co-marketing partners, etc..
• To receive news right in time
Get your personal copy every monday delivered by e-mail.
Why should you use R&D Pipeline N ?
Learn more about R&D Pipeline News
R&D Pipeline News is your weekly tool for biopharmaceutical R&D analysis and it's available by annual subscription. R&D Pipeline News will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given Target, Technology or Company.
The R&D information is presented in an easy- and rapid-to-screen tabular format and grouped either in Therapeutic Areas or Product Categories, saving you time in your research.
Where can I get a subscription?
At our Online Store: http://www.pipelinereview.com/store/periodicals.html
Or contact us at [email protected]